Detalles de la búsqueda
1.
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
Ann Hematol
; 102(12): 3383-3399, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37792065
2.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol
; 16(16): 1691-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26549589
3.
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Trials
; 24(1): 591, 2023 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37715270
4.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Lancet Haematol
; 9(11): e810-e821, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36328040
5.
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Blood Adv
; 5(13): 2707-2716, 2021 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34196677
6.
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Trials
; 22(1): 765, 2021 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34732236
7.
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
Leukemia
; 35(9): 2517-2525, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33603142
8.
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Haematologica
; 94(3): 414-8, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19252176
9.
Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
J Cancer Res Clin Oncol
; 144(8): 1531-1538, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29761371
10.
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
J Cancer Res Clin Oncol
; 143(6): 1023-1034, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28197787
11.
Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.
Indian J Hematol Blood Transfus
; 28(2): 67-76, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23730012
12.
Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg.
Dig Dis
; 24(1-2): 207-11, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16699280
13.
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.
Oncology
; 68(4-6): 326-32, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16020959
Resultados
1 -
13
de 13
1
Próxima >
>>